Literature DB >> 1989916

Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study.

C P Morrow1, B N Bundy, R J Kurman, W T Creasman, P Heller, H D Homesley, J E Graham.   

Abstract

Between June 20, 1977 and February 5, 1983, the Gynecologic Oncology Group entered 1180 women with clinical stage I or II (occult) endometrial carcinoma into a surgical-pathological staging study. Eight hundred ninety-five patients with endometrioid or adenosquamous carcinoma were evaluable for this study which relates surgical-pathological parameters and postoperative treatment to recurrence-free interval and recurrence site. Proportional hazards modeling of time to recurrence was performed. For patients without metastasis determined by surgical-pathological staging the greatest determinant of recurrence was grade 3 histology adenocarcinoma grade 3, relative risk (RR) = 15; adenosquamous carcinoma grade 3, RR = 8.1; all adenocanthomas, RR = 1.0). Of 48 patients with histologically documented aortic node metastases, 47 had one or more of the following features: (1) grossly positive pelvic nodes, (2) grossly positive adnexal metastasis, or (3) outer one-third myometrial invasion. Pelvic radiation was administered to 48.0% and vaginal brachytherapy alone to 10.2% of patients postoperatively; 41.8% received no adjuvant radiation therapy. None of three recurrences in the vaginal implant group were vaginal or pelvic; 7.4% (7 of 95) of recurrences in the pelvic radiation therapy (RT) group were vaginal and 16.8% were pelvic; 18.2% (8 of 44) of recurrences in the no adjuvant radiation group were vaginal and 31.8% pelvic. Because of the high degree of selection bias no valid comparisons can be made of recurrence-free interval in these groups. The 5-year recurrence-free interval for patients with negative surgical-pathological risk factors (other than grade and myoinvasion) was 92.7%; involvement of the isthmus/cervix 69.8%; positive pelvic cytology 56.0%; vascular space invasion 55.0%; pelvic node or adnexal metastases 57.8%; and aortic node metastases or gross laparotomy findings 41.2%. It is not clear that cervix invasion per se diminishes survival, because it is more often associated with poor tumor differentiation (34.7% versus 24.0%, grade 3) and deep myoinvasion (47.0 vs 18.6%) than cases without cervix invasion. The relapse rate among cervix-positive and -negative cases with grade 3 lesions and deep myoinvasion is not dramatically different (48.8% vs 39.8%). The proportion of failures which were vaginal/pelvic (34.6% for the surgery only group compared to 12.5% of the RT group) appears to favor the use of adjuvant radiation for patients with more than one-third myoinvasion and grade 2 or 3 tumor. There were 97 patients in the study group with malignant cytology of which 29.1% had regional/distant failure, which compares to 10.5% of the cytology-negative patients.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Year:  1991        PMID: 1989916     DOI: 10.1016/0090-8258(91)90086-k

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  174 in total

1.  Management of stage 1 endometrial carcinoma. Postoperative radiotherapy is not justified in women with medium risk disease.

Authors:  M P Burger
Journal:  BMJ       Date:  2001-03-10

2.  Prognostic factors in stages II/III/IV and stages III/IV endometrioid and serous adenocarcinoma of the endometrium.

Authors:  P Mhawech-Fauceglia; R F Herrmann; J Kesterson; I Izevbaye; S Lele; K Odunsi
Journal:  Eur J Surg Oncol       Date:  2010-12       Impact factor: 4.424

3.  Radiotherapy: Intermediate-risk endometrial cancer--adjuvant treatment.

Authors:  Patricia J Eifel
Journal:  Nat Rev Clin Oncol       Date:  2010-10       Impact factor: 66.675

4.  Endometrial cancer.

Authors:  Kimberly K Leslie; Kristina W Thiel; Michael J Goodheart; Koen De Geest; Yichen Jia; Shujie Yang
Journal:  Obstet Gynecol Clin North Am       Date:  2012-06       Impact factor: 2.844

5.  Costs and benefits of routine follow-up after curative treatment for endometrial cancer.

Authors:  O O Agboola; E Grunfeld; D Coyle; G A Perry
Journal:  CMAJ       Date:  1997-10-01       Impact factor: 8.262

6.  DICER1 expression and outcomes in endometrioid endometrial adenocarcinoma.

Authors:  Israel Zighelboim; Andrew J Reinhart; Feng Gao; Amy P Schmidt; David G Mutch; Premal H Thaker; Paul J Goodfellow
Journal:  Cancer       Date:  2010-11-08       Impact factor: 6.860

7.  How low is low enough? Evaluation of various risk-assessment models for lymph node metastasis in endometrial cancer: a Korean multicenter study.

Authors:  Sokbom Kang; Jong-Min Lee; Jae-Kwan Lee; Jae Weon Kim; Chi-Heum Cho; Seok-Mo Kim; Sang-Yoon Park; Chan-Yong Park; Ki-Tae Kim
Journal:  J Gynecol Oncol       Date:  2012-09-19       Impact factor: 4.401

8.  Analysis of recurrence and survival rates in grade 3 endometrioid endometrial carcinoma.

Authors:  Jieyu Wang; Nan Jia; Qing Li; Chao Wang; Xiang Tao; Keqin Hua; Weiwei Feng
Journal:  Oncol Lett       Date:  2016-07-28       Impact factor: 2.967

9.  Laparoscopic versus abdominal hysterectomy for endometrial cancer: comparison of patient outcomes.

Authors:  Gary S Leiserowitz; Guibo Xing; Arti Parikh-Patel; Rosemary Cress; Alireza Abidi; Anne O Rodriguez; John L Dalrymple
Journal:  Int J Gynecol Cancer       Date:  2009-11       Impact factor: 3.437

10.  Prognostic value of histological grading in ductal adenocarcinoma of the pancreas. Klöppel vs TNM grading.

Authors:  P C Giulianotti; U Boggi; G Fornaciari; J Bruno; G Rossi; D Giardino; G Di Candio; F Mosca
Journal:  Int J Pancreatol       Date:  1995-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.